SOURCE: Medivation

Medivation

March 02, 2012 16:30 ET

Medivation Announces Participation at Upcoming Investor Conferences

SAN FRANCISCO, CA--(Marketwire - Mar 2, 2012) - Medivation, Inc. (NASDAQ: MDVN) today announced that it will present at the following conferences in March:

  • Patrick Machado, chief business and financial officer, will present at Cowen and Company's 32nd Annual Healthcare Conference on Tuesday, March 6 at 8:00a.m. Eastern Time.
  • David Hung, M.D., president and chief executive officer, will present at Barclays Capital Global Healthcare Conference on Tuesday, March 13 at 8:30a.m. Eastern Time.

About Medivation
Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. Together with its corporate partner Astellas, Medivation currently has its investigational drug MDV3100 in Phase 3 development to treat advanced prostate cancer. For more information, please visit us at www.medivation.com.

Contact Information

  • Contacts:
    Patrick Machado
    Chief Business & Financial Officer
    (415) 829-4101

    Anne Bowdidge
    Sr. Director, Investor Relations
    (650) 218-6900